Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
At P-Values, you’ll find updates, perspective, insights and information from staff and partners working on the frontlines of research, advocacy and implementation. P-value is a statistical term for the probability that a trial result is reliable and not the outcome of chance.
Blog Post
The STI & HIV World Congress brought together over 1,400 researchers, healthcare providers, advocates, funders and more in Montreal last week, where they shared urgent insights, promising innovations, and calls to action. The gathering came at a pivotal moment when rates of STIs are rising globally, amid massive disruptions caused by shifts in US policies and funding and decreased investments from other funders.
Blog Post
AVAC condemns a series of actions taken by the U.S. presidential administration to dismantle U.S. leadership in research, development and delivery of lifesaving vaccines. Without U.S. government leadership, the country and the world will remain woefully unprepared for ongoing and emerging pandemic threats.
Blog Post
Last Friday, the European Medicines Agency recommended injectable lenacapavir for PrEP. This comes amid more political chaos this week that threatens delivery including, a surprise funding freeze and its reversal, a new whistleblower report on the unlawful foreign aid freeze, changes in NIH policies and continued dismantling of federal advisory boards.
showing 1-10 of 1117
The STI & HIV World Congress brought together over 1,400 researchers, healthcare providers, advocates, funders and more in Montreal last week, where they shared urgent insights, promising innovations, and calls to action. The gathering came at a pivotal moment when rates of STIs are rising globally, amid massive disruptions caused by shifts in US policies and funding and decreased investments from other funders.
AVAC condemns a series of actions taken by the U.S. presidential administration to dismantle U.S. leadership in research, development and delivery of lifesaving vaccines. Without U.S. government leadership, the country and the world will remain woefully unprepared for ongoing and emerging pandemic threats.
Last Friday, the European Medicines Agency recommended injectable lenacapavir for PrEP. This comes amid more political chaos this week that threatens delivery including, a surprise funding freeze and its reversal, a new whistleblower report on the unlawful foreign aid freeze, changes in NIH policies and continued dismantling of federal advisory boards.
Momentum continues to build for injectable lenacapavir (LEN) for PrEP as what could be one of the most transformational moments in HIV prevention ever. Check out AVAC’s resources below (all newly updated) to help advocates track, explain, and take action to meet the moment.
This week’s issue covers what’s next with PEPFAR and a new bill in the US Congress that aims to restore its prevention programs. It also highlights a new funding bill that supports global health R&D and spotlights the shocking destruction of contraception and vaccines bound for Africa. Plus: key takeaways from IAS 2025 and what they mean for the future of HIV prevention.
The IAS 2025 conference in Kigali will go down as a critical turning point in the history of the HIV response. Every session, every meeting, every presentation played out against an existential threat: will the world find the will to end the HIV epidemic, with tremendous advances in technology underway, or will the momentum seen through 2024 collapse as evidence-based interventions fall way to ideology?
This week’s Global Health Watch highlights major developments in HIV prevention science and policy, spotlighted at the IAS 2025 conference in Kigali, Rwanda. From new WHO guidelines recommending injectable lenacapavir for PrEP to Merck’s once-monthly PrEP pill advancing to Phase 3 trials, the HIV prevention pipeline is expanding and evolving. All this amid an increasingly intense fight to protect global health funding.
The 13th International AIDS Society Conference on HIV Science, started this week amidst unifying calls to confront the collapse of US support for the HIV response with commitments to reimagine funding, research, development and programming aimed at sustaining progress toward ending the epidemic.
This week the Global Fund and Gilead announced next steps in the process to rollout injectable lenacapavir, the new UNAIDS Global AIDS Update was released, and South Africa saw a partial reprieve for NIH-funded research. We also track AVAC’s court case against the foreign aid freeze and Congressional advocacy to protect NIH funding.
This year’s IAS Conference comes at a defining moment. Dramatic scientific advances are within reach, but global funding cuts are placing these innovations at risk. All this is jeopardizing the gains that communities, advocates, and researchers have fought for decades to achieve. Click for more, including our roadmap highlighting sessions where prevention and the larger issues of global health equity and sustainability are in the spotlight.
showing 1-10 of 1117
Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
AVAC’s email list for organization and individuals interested in timely updates and critical perspectives on developments in biomedical HIV prevention.
A comprehensive round-up of HIV prevention media coverage and scientific publications.
Each month this podcast uses interviews, discussion and first-person reflections to explore vital topics confronting the field of HIV prevention research.
PxWire is AVAC’s quarterly update on biomedical HIV prevention. Each issue highlights key developments, challenges and opportunities, and features a centerspread infographic that provides a visual tool for framing these issues.
Pandemic Watch is a curated news digest on the latest pandemic prevention, preparedness, and response (PPPR) news and resources.
A collection of official statements from AVAC.
Media clippings featuring AVAC, its staff and close partners in the news media.